Clinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far?

Simple item page
dc.catalogadorjca
dc.contributor.authorWaissbluth Abarca, Sofía
dc.date.accessioned2025-03-11T14:15:53Z
dc.date.available2025-03-11T14:15:53Z
dc.date.issued2020
dc.description.abstractBackground Cisplatin (CDDP) chemotherapy can cause serious side effects including irreversible and progressive hearing loss. Studies have aimed to assess potential protective strategies; however, systemic treatments have presented variable results, and potential interactions with CDDP have limited clinical trials. Methods A review of the literature was performed in order to evaluate clinical trials that have studied a transtympanic approach as an otoprotectant strategy. Results Six clinical trials were included. While a transtympanic approach can limit side effects and avoid interactions with CDDP, recurrent issues have been expressed including which otoprotectant to test, time delays between CDDP treatment and transtympanic injections, side effects such as pain and dizziness, concentrations, and number of injections. Clinical trials have used sodium thiosulfate, N-acetylcysteine and dexamethasone. Conclusions While a transtympanic approach seems like an attractive strategy, further research is needed to clarify which is the optimal otoprotectant, its dosage, and the number of injections.
dc.format.extent10 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1007/s00405-020-06003-w
dc.identifier.eissn1434-4726
dc.identifier.issn0937-4477
dc.identifier.pubmedid32358651
dc.identifier.urihttps://doi.org/10.1007/s00405-020-06003-w
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/102484
dc.identifier.wosidWOS:000529775500001
dc.information.autorucEscuela de Medicina; Waissbluth Abarca, Sofía; 0000-0002-6884-968X; 252738
dc.issue.numero9
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final2422
dc.pagina.inicio2413
dc.revistaEuropean Archives of Oto-Rhino-Laryngology
dc.rightsacceso restringido
dc.subjectTranstympanic
dc.subjectCisplatin
dc.subjectOtoprotectant
dc.subjectHearing loss
dc.subjectClinical trial
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleClinical trials evaluating transtympanic otoprotectants for cisplatin-induced ototoxicity: what do we know so far?
dc.typeartículo de revisión
dc.volumen277
sipa.codpersvinculados252738
Files
Collections
Artículos de revistas